Clinical and Quality-of-Life Outcomes of Omalizumab Treatment in Chronic Spontaneous Urticaria.
Аннотация
AIMS: To evaluate response to omalizumab in chronic spontaneous urticaria (CSU), assess concordance between symptom and quality-of-life scores, and identify predictors of response.
METHODS
Single-centre retrospective review of adults with CSU treated with omalizumab in a dermatology department in the Midwest of Ireland. Data included demographics, disease duration, and baseline and latest Urticaria Severity Score (USS), Dermatology Life Quality Index (DLQI), and itch and rash scores. Responders were defined as ≥50% USS improvement. Associations were analysed using Spearman's correlation and Cohen's κ.
RESULTS
Thirty-six patients were included; 22 (61%) responded, including 11 complete responders. Complete responders had lower baseline USS and DLQI. Correlations between USS and other measures were moderate, with slight-moderate agreement.
DISCUSSION: Omalizumab improved CSU outcomes. Lower baseline severity predicted complete response, while symptom and quality-of-life improvements showed limited individual concordance.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.